Novoeight (Antihemophilic factor [recombinant]) for Hemophilia

Overview
Novoeight is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with hemophilia A. Novoeight can also be used for perioperative (before, during, and after surgery) care and routine prophylaxis. The technical name of Novoeight is Antihemophilic factor (recombinant).

Novoeight is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.

How do I take it?
Prescribing information states that Novoeight is given as an intravenous injection.

Novoeight comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Novoeight lists common side effects including fever, pain or irritation at injection sites, and changes in liver enzyme test results.

Rare but serious side effects listed for Novoeight include systemic allergic reactions and the development of inhibitors.

For more details about this treatment, visit:

Novoeight.com

Treatment of Hemophilia – Hemophilia Federation of America